Revision as of 03:40, 28 September 2013

Achievement

Consideration

safety

We have considered and organized the safety, such as the chassis organisms, their risk group and derivation can be checked from this Safety page.

ethics

We have to kill transformed E. coli in order to attain the target plasmid because many BioBrick parts are derived from organisms. However, the BioBrick parts iGEM Kyoto submitted this year are all synthesized. Therefore, the problems of ethics are completely solved. Certainly, treating artificial life has some ethical problems, but this is a considerable and long-term issue closely related to the development of synthetic biology. In our Human Practice project, we carried out an attitude survey on bioethics which is closely connected with our iGEM activities. Then, we discussed the results with a professor, who belongs to the Graduate School of Letters, Kyoto University. This discussion led us to revise our attitude towards the subsequent approaches of Human Practice project.

ownership and sharing

When we want to share parts coding proteins, we have to construct, amplify and extract target plasmid and send them in a lot of cases. Frankly speaking, this is troublesome. However, BioBrick parts iGEM Kyoto submitted this year are only about a few hundred base pair, and are all synthesized. Just by sharing the information of the sequences, you can get these parts in the same conditions Therefore, we can easily share them compared to other parts coding proteins.

New approach to Human Practice

We have continued our Human Practice activity considering the result of survey held by iGEM Kyoto in 2010. In addition, we revised previous approach and dealed with new one of Human Practice activities.

Support for iGEM Biwako_Nagahama

We have helped iGEM Biwako_Nagahama team holding study meeting and editing wiki.

</div> </div>

@@ Line 3: / Line 3: @@
 <div class="texts">
 =Achievement=
-==safety==
+==Consideration==
-We have considered and summarized on safety such as the chassis organisms, their risk groups and the derivation of genes below.<br><br>
+<br>
-==ethics==
+===safety===
-今までのほとんどのパーツは生物由来のものであったため、遺伝子断片を取り出すために由来となる細胞を殺す必要があったが、今回のパーツは人工的に合成したもので、生物由来でないため由来となる細胞が死ぬことはなく、その点の倫理問題は解消される。問題となってくるのは、生体分子と同じ要素によって構成された人工物を細胞内に組み込むという、人工生命に対する扱いであるが、これは合成生物学が今後も長く付き合っていく問題であろう。
+We have considered and organized the safety, such as the chassis organisms, their risk group and derivation can be checked from this Safety page.<br>
-Many genetic parts which have been used are got from living things,so in order to get genetic parts, we must kill cells which have genetic parts we want.But genetic parts we used this time were artificially made,so we did not kill cells to get genetic parts.In our way of experiment,ethical problem that living things are killed to get genetic parts dose not happen.Next problem is that in cells  we insert artificial things which have same elements as living things have.As people who study synthetic biology, We must continue to consider about this problem.
+===ethics===
+We have to kill transformed E. coli in order to attain the target plasmid because many BioBrick parts are derived from organisms. However, the BioBrick parts iGEM Kyoto submitted this year are all synthesized.
+Therefore, the problems of ethics are completely solved.
+Certainly, treating artificial life has some ethical problems, but this is a considerable and long-term issue closely related to the development of synthetic biology. In our Human Practice project, we carried out an attitude survey on bioethics which is closely connected with our iGEM activities. Then, we discussed the results with a professor, who belongs to the Graduate School of Letters, Kyoto University. This discussion led us to revise our attitude towards the subsequent approaches of Human Practice project.<br>
+===ownership and sharing===
+When we want to share parts coding proteins, we have to construct, amplify and extract target plasmid and send them in a lot of cases. Frankly speaking, this is troublesome.
+However, BioBrick parts iGEM Kyoto submitted this year are only about a few hundred base pair, and are all synthesized.
+Just by sharing the information of the sequences, you can get these parts in the same conditions
+Therefore, we can easily share them compared to other parts coding proteins.<br>
+==New approach to Human Practice==
+We have continued our Human Practice activity considering the result of survey held by iGEM Kyoto in 2010. In addition, we revised previous approach and dealed with new one of Human Practice activities. <br>
+==Support for iGEM Biwako_Nagahama==
+We have helped iGEM Biwako_Nagahama team holding study meeting and editing wiki.
-英訳案２
-Almost all the parts are from creatures so far, as a result, we have to kill the cells when taking the sections of genes out. Because the parts we used are artificially synthesized this time, there’s no need to kill the cells, so that this ethical problem is avoided. The problem is how we should treat the behavior that integrating artifact of the same composition with biomolecules into cells. This is also a problem synthetic biology will face during a long term.
-In our Human Practice project, we carried out a survey towards attitude on bioethics which is closely conected with iGEM. And then, a professor, who belongs to Graduate School of Letters, Kyoto University. And this leaded to revising subsequent approaches of Human Practice project.<br><br>
-==ownership/sharing==
-今年のパーツは全て由来が人工合成で、どれも人工合成可能な長さなので、シーケンス情報を共有するだけで全く同じ条件のパーツが作成可能である。人工合成不可能でプラスミドを増やしクローニングを行ってそのものを送らないと共有できない多くのタンパク質のパーツと比べて、shareがより容易になるだろう。<br>
-For the reason that all the parts are artificially synthesized, and of the proper length that is possible to be artificially synthesized this year, parts that are completely same can be synthesized simply by sharing the information of the sequences. It is apparently simple to share compared with most of the parts of protein which can’t be synthesized artificially, and can be only obtained by cloning via plasmid.
-英訳案２
-Only by sharing information sequence, everyone can make completely the same genetic parts ,because all genetic parts making RNA which we used this year were made artificially and they are short .Many genetic parts making proteins are unable to be made artificially,so we cannot share them without increasing plasmids, cloning them ,and sending themself.Therefore our parts making RNA are easier to share than them.
+</div>
+</div>
+{{Kyoto/import|pagename={{PAGENAME}}}}
+{{Kyoto/js}}
+{{Kyoto/footer}}
 </div>
 </div>

Team:Kyoto/Achievement

From 2013.igem.org